Serious ADRs with ocular triamcinolone/moxifloxacin product

Serious ADRs with ocular triamcinolone/moxifloxacin product Reactions 1664, p4 - 12 Aug 2017 Serious ADRs with ocular triamcinolone/moxifloxacin product A compounded drug product containing triamcinolone (i.e. steroid) and moxifloxacin (i.e. anti- infective) is associated with serious ADRs, according to a US FDA Safety Alert. This product – which is compounded by Guardian Pharmacy Services (Dallas, Texas) – is intended for intravitreal injection following cataract surgery for postoperative prophylaxis of ocular inflammation and endophthalmitis; the expectation is that the patient would not require postoperative eye drops. The FDA received adverse event (AE) reports on 5 April and 1 June this year relating to at least 43 patients who had received intravitreal injections of the above- mentioned triamcinolone/moxifloxacin product following cataract surgery, which was performed at two different surgery centres in Dallas. Several months after their operations, these patients developed a variety of symptoms, including: vision impairment, poor night vision, loss of colour perception, photophobia, glare, halos, flashing lights, ocular discomfort, pain, loss of balance, headaches, and/or nausea. Some of these AEs mentioned did not occur until at least 1 month following the cataract surgery. During follow-up examinations of patients treated at the Park Central Surgical Center, physicians found that patients who received the triamcinolone/moxifloxacin product experienced decreased visual function that involved visual acuity and visual fields. Initial optical tests revealed macular oedema, followed by some cases of retinal degeneration. During the 5-month postoperative period, some patients reported symptom improvements, but a number of patients continued to experience "a significant reduction in best-corrected visual acuity and visual fields", stated the FDA. Both patients and healthcare professionals are encouraged to report AEs related to this compounded triamcinolone/moxifloxacin product to the FDA’s MedWatch programme. US Food and Drug Administration. Compounded Triamicinolone and Moxifloxacin Product for Intravitreal Injection by Guardian Pharmacy Services: Alert to Health Professionals - Serious Adverse Events Reported. Internet Document : 28 Jul 2017. Available from: URL: https://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm569123.htm 803263660 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Serious ADRs with ocular triamcinolone/moxifloxacin product

Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/serious-adrs-with-ocular-triamcinolone-moxifloxacin-product-nCRirbe5Oq
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-34284-1
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial